Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsPier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.JAMA Network Open|April 2, 2020
Geographic Distribution of Racial Differences in Prostate Cancer MortalitySean A Fletcher, Maya Marchese, Alexander P Cole, et al.Journal for Immunotherapy of Cancer|November 9, 2019
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanomaMarieke J Krimphove, Karl H Tully, David F Friedlander, et al.Urologic Oncology|December 23, 2019
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysisWei Shen Tan, Quoc-Dien Trinh, Matthew H Hayn, et al.The Prostate|July 30, 2025
Racial Disparities in the Use of MRI and PET Scan Among Medicare Beneficiaries With Prostate CancerHanna Zurl, Klara K Pohl, Stephan M Korn, et al.Urology Practice|April 28, 2026
Variability and Hospital-Level Predictors of MRI for Elevated PSA: Results of a Medicare and American Hospital Association LinkageAndrea Piccolini, Stephan Korn, Zhiyu Qian, et al.JNCI Cancer Spectrum|May 16, 2025
Disparities in Tissue-based Biomarker Testing Among U.S. Medicare Beneficiaries with Prostate CancerStephan M Korn, Zhiyu Qian, Hanna Zurl, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low UptakeStephan M Korn, Zhiyu Qian, Hanna Zurl, et al.Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 4, 2025
Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort studyStephan M Korn, Zhiyu Qian, Hanna Zurl, et al.Cancer Immunology, Immunotherapy : CII|August 23, 2022
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinomaGuru P Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, et al.Pageof 4